AARVIK THERAPEUTICS Trademark

Trademark Overview

On Thursday, August 12, 2021, a trademark application was filed for AARVIK THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AARVIK THERAPEUTICS trademark a serial number of 90879874. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Friday, January 2, 2026. This trademark is owned by Aarvik Therapeutics, Inc.. The AARVIK THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research for medical purposes in the field of cancer, infectious and neurologic diseases and disorders; research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of mono-specific antibodies, bi-specific, multi-specific antibodies; antibody-drug conjugates, T cell, NK cell, and Macrophage engaging antibodies; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, infectious and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research development and establishment of testing specifications and procedures in the field of cancer research, and scientific research in the field of cancer diagnosis and treatment; Providing scientific research information in the field...
aarvik therapeutics

General Information

Serial Number90879874
Word MarkAARVIK THERAPEUTICS
Filing DateThursday, August 12, 2021
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateFriday, January 2, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 31, 2022

Trademark Statements

NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesScientific research for medical purposes in the field of cancer, infectious and neurologic diseases and disorders; research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of mono-specific antibodies, bi-specific, multi-specific antibodies; antibody-drug conjugates, T cell, NK cell, and Macrophage engaging antibodies; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, infectious and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research development and establishment of testing specifications and procedures in the field of cancer research, and scientific research in the field of cancer diagnosis and treatment; Providing scientific research information in the field of cancer research, and providing scientific research information in the field of cancer diagnosis and treatment

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 4, 2021
Primary Code042
First Use Anywhere DateSunday, December 31, 2023
First Use In Commerce DateSunday, December 31, 2023

Trademark Owner History

Party NameAarvik Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHayward, CA 94544
Party NameAarvik Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFremont, CA 94555

Trademark Events

Event DateEvent Description
Monday, August 16, 2021NEW APPLICATION ENTERED
Monday, October 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 10, 2022ASSIGNED TO EXAMINER
Thursday, March 17, 2022NON-FINAL ACTION WRITTEN
Thursday, March 17, 2022NON-FINAL ACTION E-MAILED
Thursday, March 17, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 26, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 30, 2022ASSIGNED TO LIE
Thursday, March 31, 2022LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, April 12, 2022WITHDRAWN FROM PUB - OG REVIEW QUERY
Wednesday, April 13, 2022PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, April 20, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 20, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, April 20, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 20, 2022EXAMINER'S AMENDMENT ENTERED
Saturday, April 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 11, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 31, 2022PUBLISHED FOR OPPOSITION
Tuesday, May 31, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 31, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, May 31, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 31, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 28, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 26, 2022NOTICE OF ALLOWANCE CANCELLED
Monday, October 17, 2022NEW NOA TO ISSUE
Tuesday, November 29, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, January 25, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 25, 2023SOU EXTENSION 1 FILED
Wednesday, January 25, 2023SOU EXTENSION 1 GRANTED
Friday, January 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 28, 2023SOU EXTENSION 2 FILED
Tuesday, November 28, 2023SOU EXTENSION 2 GRANTED
Thursday, November 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 27, 2024SOU TEAS EXTENSION RECEIVED
Monday, May 27, 2024SOU EXTENSION 3 FILED
Monday, May 27, 2024SOU EXTENSION 3 GRANTED
Tuesday, May 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 29, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 29, 2024SOU EXTENSION 4 FILED
Saturday, November 30, 2024SOU EXTENSION 4 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 29, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, October 21, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 28, 2025SOU EXTENSION 5 FILED
Tuesday, October 21, 2025SOU EXTENSION 5 GRANTED
Tuesday, October 21, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 1, 2025TEAS STATEMENT OF USE RECEIVED
Monday, December 1, 2025USE AMENDMENT FILED
Saturday, December 27, 2025STATEMENT OF USE PROCESSING COMPLETE
Friday, January 2, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, January 2, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

therapeutics aarvik research field scientific antibodies cancer development services specific testing cell